This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

R. Capra; F. Mattioli; N. Marciano'; L. A. Vignolo
Clinica Neurologica

M. Bettinzioli; P. Airo'; R. Cattaneo
Institute of Immunology University of Brescia Piazza Spedali Civili 1 25125 Brescia, Italy

Arch Neurol. 1990;47(3):254.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Greenberg et al¹ recently reported that elevated levels of a soluble form of the interleukin 2 receptor (sIl-2r) released by activated lymphoid cells² are found in the serum samples of patients affected by chronic progressive multiple sclerosis. An increased expression of membrane-bound interleukin 2 receptor on peripheral blood lymphocytes in patients with a relapsing-remitting form of multiple sclerosis has also been described.³ Therefore, we have measured the levels of sIl-2r in the serum samples obtained from 34 patients with clinically defined⁴ relapsing-remitting multiple sclerosis using an enzyme-linked immunosorbent assay (Tcell Science, Cambridge, Mass). Nine patients (7 females, 2 males; mean age, 29.2 years) were studied during an acute exacerbation, while 25 patients (17 females, 8 males; mean age, 38.9 years) were studied in a period of clinical remission of at least 6 months' duration. None of the patients had taken steroids during the . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?